Impact of formulation and particle size on stability and immunogenicity of oil-in-water emulsion adjuvants

References

• Fenner F. Smallpox: emergence, global spread, and eradication. Hist Philos Life Sci, 1993. 15(3): p. 397-420; PMID:7529932
   PubMed Web of Science ®Google Scholar
• Vogel FR, Caillet C, Kusters IC, Haensler J. Emulsion-based adjuvants for influenza vaccines. Expert Rev Vaccines, 2009. 8(4): p. 483-92; PMID:19348563; http://dx.doi.org/10.1586/erv.09.5
   PubMed Web of Science ®Google Scholar
• Leroux-Roels G. Unmet needs in modern vaccinology: adjuvants to improve the immune response. Vaccine, 2010. 28 Suppl 3: p. C25-36; PMID:20713254; http://dx.doi.org/10.1016/j.vaccine.2010.07.021
   PubMedGoogle Scholar
• Channon HJ. The Biological Significance of the Unsaponifiable Matter of Oils: Experiments with the Unsaturated Hydrocarbon, Squalene (Spinacene). Biochem J, 1926. 20(2): p. 400-8; PMID:16743673
   PubMedGoogle Scholar
• Huang ZR, YK Lin, JY Fang. Biological and pharmacological activities of squalene and related compounds: potential uses in cosmetic dermatology. Molecules, 2009. 14(1): p. 540-54; PMID:19169201; http://dx.doi.org/10.3390/molecules14010540
   PubMed Web of Science ®Google Scholar
• Klucker MF, Dalençon F, Probeck P, Haensler J. AF03, an alternative squalene emulsion-based vaccine adjuvant prepared by a phase inversion temperature method. J Pharm Sci, 2012. 101(12): p. 4490-500; PMID:22941944; http://dx.doi.org/10.1002/jps.23311
   PubMed Web of Science ®Google Scholar
• Suli J, Benísek Z, Eliás D, Svrcek S, Ondrejková A, Ondrejka R, Bajová V. Experimental squalene adjuvant. I. Preparation and testing of its effectiveness. Vaccine, 2004. 22(25-26): p. 3464-9; http://dx.doi.org/10.1016/j.vaccine.2004.02.023
   PubMed Web of Science ®Google Scholar
• Fox CB. Squalene emulsions for parenteral vaccine and drug delivery. Molecules 2009. 14(9): p. 3286-312; PMID:19783926; http://dx.doi.org/10.3390/molecules14093286
   PubMed Web of Science ®Google Scholar
• Podda A, G Del Giudice. MF59-adjuvanted vaccines: increased immunogenicity with an optimal safety profile. Expert Rev Vaccines, 2003. 2(2): p. 197-203; http://dx.doi.org/10.1586/14760584.2.2.197
   PubMedGoogle Scholar
• Schultze V, D'Agosto V, Wack A, Novicki D, Zorn J, Hennig R. Safety of MF59 adjuvant. Vaccine, 2008. 26(26): p. 3209-22; http://dx.doi.org/10.1016/j.vaccine.2008.03.093
   PubMed Web of Science ®Google Scholar
• Fox CB, J Haensler. An update on safety and immunogenicity of vaccines containing emulsion-based adjuvants. Expert Rev Vaccines, 2013. 12(7): p. 747-58; http://dx.doi.org/10.1586/14760584.2013.811188
   PubMed Web of Science ®Google Scholar
• Garcon N, DW Vaughn, AM Didierlaurent. Development and evaluation of AS03, an Adjuvant System containing alpha-tocopherol and squalene in an oil-in-water emulsion. Expert Rev Vaccines, 2012. 11(3): p. 349-66; http://dx.doi.org/10.1586/erv.11.192
   PubMed Web of Science ®Google Scholar
• Baldridge JR, RT Crane. Monophosphoryl lipid A (MPL) formulations for the next generation of vaccines. Methods, 1999. 19(1): p. 103-7; PMID:10525445; http://dx.doi.org/10.1006/meth.1999.0834
   PubMed Web of Science ®Google Scholar
• Behzad H, Huckriede AL, Haynes L, Gentleman B, Coyle K, Wilschut JC, Kollmann TR, Reed SG, McElhaney JE. GLA-SE, a synthetic toll-like receptor 4 agonist, enhances T-cell responses to influenza vaccine in older adults. J Infect Dis, 2012. 205(3): p. 466-73; PMID:22147791; http://dx.doi.org/10.1093/infdis/jir769
   PubMed Web of Science ®Google Scholar
• Ott G, Barchfeld GL, Chernoff D, Radhakrishnan R, van Hoogevest P, Van Nest G. MF59. Design and evaluation of a safe and potent adjuvant for human vaccines. Pharm Biotechnol, 1995. 6: p. 277-96; PMID:7551221; http://dx.doi.org/10.1007/978-1-4615-1823-5_10
   PubMedGoogle Scholar
• Tripp RA. Pathogenesis of respiratory syncytial virus infection. Viral Immunol 2004. 17(2): p. 165-81; PMID:15279697; http://dx.doi.org/10.1089/0882824041310513
   PubMed Web of Science ®Google Scholar
• Anderson LJ, Dormitzer PR, Nokes DJ, Rappuoli R, Roca A, Graham BS. Strategic priorities for respiratory syncytial virus (RSV) vaccine development. Vaccine, 2013. 31 Suppl 2: p. B209-15; http://dx.doi.org/10.1016/j.vaccine.2012.11.106
   PubMed Web of Science ®Google Scholar
• Cherukuri A, Stokes KL, Patton K, Kuo H, Sakamoto K, Lambert S, Stillman E, Moore ML, Lee S. An adjuvanted respiratory syncytial virus fusion protein induces protection in aged BALB/c mice. Immun Ageing, 2012. 9(1): p. 21; PMID:23031690; http://dx.doi.org/10.1186/1742-4933-9-21
   PubMed Web of Science ®Google Scholar
• Beeler JA, K van Wyke Coelingh. Neutralization epitopes of the F glycoprotein of respiratory syncytial virus: effect of mutation upon fusion function. J Virol, 1989. 63(7): p. 2941-50; PMID:2470922
   PubMed Web of Science ®Google Scholar
• Moore ML, Chi MH, Luongo C, Lukacs NW, Polosukhin VV, Huckabee MM, Newcomb DC, Buchholz UJ, Crowe JE Jr, Goleniewska K, et al. A chimeric A2 strain of respiratory syncytial virus (RSV) with the fusion protein of RSV strain line 19 exhibits enhanced viral load, mucus, and airway dysfunction. J Virol, 2009. 83(9): p. 4185-94; PMID:19211758; http://dx.doi.org/10.1128/JVI.01853-08
   PubMed Web of Science ®Google Scholar
• Cayatte C, Schneider-Ohrum K, Wang Z, Irrinki A, Nguyen N, Lu J, Nelson C, Servat E, Gemmell L, Citkowicz A, et al. Cytomegalovirus vaccine strain towne-derived dense bodies induce broad cellular immune responses and neutralizing antibodies that prevent infection of fibroblasts and epithelial cells. J Virol, 2013. 87(20): p. 11107-20; PMID:23926341; http://dx.doi.org/10.1128/JVI.01554-13
   PubMed Web of Science ®Google Scholar
• Chanana GD, BB Sheth. Particle size reduction of emulsions by formulation design. I: Effect of polyhydroxy alcohols. J Parenter Sci Technol, 1993. 47(3): p. 130-4; PMID:8360805
   PubMedGoogle Scholar
• Chanana GD, BB Sheth. Particle size reduction of emulsions by formulation design-II: effect of oil and surfactant concentration. PDA J Pharm Sci Technol, 1995. 49(2): p. 71-6; PMID:7780748
   PubMedGoogle Scholar
• Steinhagen F, Kinjo T, Bode C, Klinman DM. TLR-based immune adjuvants. Vaccine, 2011. 29(17): p. 3341-55; PMID:20713100; http://dx.doi.org/10.1016/j.vaccine.2010.08.002
   PubMed Web of Science ®Google Scholar
• Lambert SL, Yang CF, Liu Z, Sweetwood R, Zhao J, Cheng L, Jin H, Woo J. Molecular and cellular response profiles induced by the TLR4 agonist-based adjuvant Glucopyranosyl Lipid A. PLoS One, 2012. 7(12): p. e51618; http://dx.doi.org/10.1371/journal.pone.0051618
   Web of Science ®Google Scholar
• Baudner BC, Ronconi V, Casini D, Tortoli M, Kazzaz J, Singh M, Hawkins LD, Wack A, O'Hagan DT. MF59 emulsion is an effective delivery system for a synthetic TLR4 agonist (E6020). Pharm Res, 2009. 26(6): p. 1477-85; http://dx.doi.org/10.1007/s11095-009-9859-5
   PubMed Web of Science ®Google Scholar
• Lin L, AJ Gerth, SL Peng, CpG DNA redirects class-switching towards “Th1-like” Ig isotype production via TLR9 and MyD88. Eur J Immunol, 2004. 34(5): p. 1483-7; http://dx.doi.org/10.1002/eji.200324736
   PubMed Web of Science ®Google Scholar
• Crowe JE, Jr., CY Firestone, BR Murphy. Passively acquired antibodies suppress humoral but not cell-mediated immunity in mice immunized with live attenuated respiratory syncytial virus vaccines. J Immunol, 2001. 167(7): p. 3910-8; http://dx.doi.org/10.4049/jimmunol.167.7.3910
   PubMed Web of Science ®Google Scholar